Galectin Therapeutics Inc.
DE ˙ DB ˙ US3632252025
1,88 € 0,00 (0,00%)
2026-06-04
AKTIENPREIS
SecurityDE:PHPN / Galectin Therapeutics Inc.
InstitutionJpmorgan Chase & Co
Latest Disclosed Ownership11,043 shares
Latest Disclosed Value $ 28,381
Jpmorgan Chase & Co ownership in PHPN / Galectin Therapeutics Inc.

On May 13, 2026 - Jpmorgan Chase & Co filed a 13F-HR/A form disclosing ownership of 11,043 shares of Galectin Therapeutics Inc. (DE:PHPN) valued at $24,736 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 11, 2026 disclosing 11,043 shares of Galectin Therapeutics Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $20,761 USD.

Jpmorgan Chase & Co has a history of taking positions in derivatives of the underlying security (PHPN) in the form of stock options.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:PHPN / Galectin Therapeutics Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F/A-1 GALECTIN THERAPEUTICS COMMON 363225202 11,043 0 0.00 28 -37.78 0.0000
2026-05-13 2026-03-31 13F GALECTIN THERAPEUTICS COMMON 363225202 0 -100.00 0
2026-02-11 2025-12-31 13F GALECTIN THERAPEUTICS COMMON 363225202 11,043 -4,427 -28.62 46 -30.77 0.0000
2025-11-26 2025-09-30 13F/A-1 GALECTIN THERAPEUTICS COMMON 363225202 15,470 3,133 25.40 66 150.00 0.0000
2025-11-07 2025-09-30 13F GALECTIN THERAPEUTICS COMMON 363225202 15,470 3,133 66 0.0000
2025-08-12 2025-06-30 13F GALECTIN THERAPEUTICS COMMON 363225202 12,337 -4,628 -27.28 26 30.00 0.0000
2025-05-12 2025-03-31 13F GALECTIN THERAPEUTICS COMMON 363225202 16,965 -42,728 -71.58 21 -74.03 0.0000
2025-02-12 2024-12-31 13F GALECTIN THERAPEUTICS COMMON 363225202 59,693 29,065 94.90 77 -8.33 0.0000
2024-12-26 2024-09-30 13F/A-1 GALECTIN THERAPEUTICS COMMON 363225202 30,628 18,907 161.31 84 223.08 0.0000
2024-11-08 2024-09-30 13F GALECTIN THERAPEUTICS COMMON 363225202 30,628 18,907 84 0.0000
2024-12-26 2024-06-30 13F/A-1 GALECTIN THERAPEUTICS COMMON 363225202 11,721 9,850 526.46 26 550.00 0.0000
2024-08-12 2024-06-30 13F GALECTIN THERAPEUTICS COMMON 363225202 11,721 9,850 26 0.0000
2024-12-26 2024-03-31 13F/A-1 GALECTIN THERAPEUTICS COMMON 363225202 1,871 48 2.63 4 33.33 0.0000
2024-05-10 2024-03-31 13F GALECTIN THERAPEUTICS COMMON 363225202 1,871 48 4 0.0000
2024-12-26 2023-12-31 13F/A-1 GALECTIN THERAPEUTICS COMMON 363225202 1,823 1,730 1,860.22 3 0.0000
2024-02-12 2023-12-31 13F GALECTIN THERAPEUTICS COMMON 363225202 1,823 1,730 3 0.0000
2023-11-14 2023-09-30 13F GALECTIN THERAPEUTICS COMMON 363225202 93 50 116.28 0 0.0000
2023-08-11 2023-06-30 13F GALECTIN THERAPEUTICS COMMON 363225202 43 0 0.00 0 0.0000
2023-05-18 2023-03-31 13F/A-1 GALECTIN THERAPEUTICS COMMON 363225202 43 0 0.00 0 0.0000
2023-05-11 2023-03-31 13F GALECTIN THERAPEUTICS COMMON 363225202 43 0 0 0.0000
2023-02-13 2022-12-31 13F GALECTIN THERAPEUTICS COMMON 363225202 43 0 0.00 0 0.0000
2022-11-14 2022-09-30 13F GALECTIN THERAPEUTICS COMMON 363225202 43 0 0.00 0 0.0000
2022-08-11 2022-06-30 13F GALECTIN THERAPEUTICS COMMON 363225202 43 0 0.00 0 0.0000
2022-05-11 2022-03-31 13F GALECTIN THERAPEUTICS COMMON 363225202 43 0 0.00 0 0.0000
2022-02-11 2021-12-31 13F/A-1 GALECTIN THERAPEUTICS COMMON 363225202 43 0 0.00 0 0.0000
2022-02-10 2021-12-31 13F GALECTIN THERAPEUTICS COMMON 363225202 43 0 0 0.0000
2021-11-12 2021-09-30 13F GALECTIN THERAPEUTICS COMMON 363225202 43 0 0.00 0 0.0000
2021-08-12 2021-06-30 13F GALECTIN THERAPEUTICS COMMON 363225202 43 -100,512 -99.96 0 -100.00
2021-05-12 2021-03-31 13F GALECTIN THERAPEUTICS COMMON 363225202 100,555 -3,158 -3.04 218 -6.03 0.0000
2021-02-19 2020-12-31 13F/A-1 GALECTIN THERAPEUTICS COMMON 363225202 103,713 82,039 378.51 232 222.22 0.0000
2021-02-11 2020-12-31 13F GALECTIN THERAPEUTICS COMMON 363225202 103,713 82,039 232 5.7375
2020-11-12 2020-09-30 13F/A-1 GALECTIN THERAPEUTICS COMMON 363225202 21,674 -6,337 -22.62 72 -15.29 0.0000
2020-11-12 2020-09-30 13F GALECTIN THERAPEUTICS COMMON 363225202 21,674 72
2020-08-11 2020-06-30 13F GALECTIN THERAPEUTICS COMMON 363225202 28,011 -12,588 -31.01 85 7.59 0.0000
2020-05-12 2020-03-31 13F GALECTIN THERAPEUTICS COMMON 363225202 40,599 27,467 209.16 79 107.89 0.0000
2020-02-11 2019-12-31 13F GALECTIN THERAPEUTICS COMMON 363225202 13,132 0 0.00 38 -20.83 0.0000
2019-11-12 2019-09-30 13F GALECTIN THERAPEUTICS COMMON 363225202 13,132 2,996 29.56 48 17.07 0.0000
2019-08-07 2019-06-30 13F GALECTIN THERAPEUTICS COMMON 363225202 10,136 -178,555 -94.63 41 -95.75 0.0000
2019-05-07 2019-03-31 13F GALECTIN THERAPEUTICS COMMON 363225202 188,691 188,691 964 0.0002
2014-08-14 2014-06-30 13F GALECTIN THERAPEUTICS COMMON 363225202 0 -10,745 -100.00 0 -100.00
2014-05-15 2014-03-31 13F GALECTIN THERAPEUTICS COMMON 363225202 10,745 10,745 165 0.0000
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-02-11 2019-12-31 13F GALECTIN THERAPEUTICS OPTION Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-11-12 2019-09-30 13F GALECTIN THERAPEUTICS OPTION Put 4,000 0.00 15 -6.25 n/a n/a n/a
2019-08-07 2019-06-30 13F GALECTIN THERAPEUTICS OPTION Put 4,000 16 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.